Drug intelligence / Profile preview

NN-843

Development stage: Preclinical
Lead developer: NanoNewron
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

NN-843 is a bispecific nanobody heterotrimer developed by NanoNewron for the treatment of Alzheimer's disease. The drug candidate utilizes the proprietary NewroBus platform, which consists of nanobodies targeting the Transferrin Receptor 1 (TfR1) to facilitate transport across the blood-brain barrier (BBB) via receptor-mediated transcytosis. The therapeutic component of the construct is a nanobody designed to neutralize Tumor Necrosis Factor alpha (TNF-α), a pro-inflammatory cytokine that plays a central role in neuroinflammation and the progression of neurodegenerative diseases. By combining the BBB-crossing shuttle with a potent anti-TNF-α inhibitor, NN-843 aims to deliver therapeutic activity directly into the central nervous system to mitigate the neuroinflammatory processes associated with Alzheimer's disease. It is currently in the preclinical stage of development.

Other names: NanoNewron-TNF-α-TfR1-bispecific nanobody heterotrimerNewroBus + TNF-α inhibitor

Targets

TNFA (Tumor necrosis factor alpha (soluble))TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on NN-843.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NN-843.

Explore the full profile